Aurobindo Q1 Profit Falls Despite EU Growth

  Published 8 months ago

Aurobindo Pharma's Q1 FY26 PBT dropped 8.8% YoY; Europe and ARV segments showed robust growth amid margin pressures.

  • European revenue grew 18% YoY to Rs 2,338 crore; US sales declined 1.9%, impacted by seasonal and destocking effects.
  • EBITDA margin shrank 102 bps YoY to 20.4%; API business revenue fell 16.1% while ARV business jumped 55.2%.
  • Interim dividend of Rs 4/share announced; record date set as 8 August, payout by 21 August 2025.

You might like these

Prostarm's BESS Expansion Boosts India's Energy Market

China's Exports Slow, Deflation Worsens Amid U.S. Tariffs

Waaree Energies Boosts ISTS with Solar Project

Amazon's India Quick-Commerce Challenge

Amazon & bolttech Boost CX with Generative AI

Enviro Infra Engineers Expands Renewable & EPC Projects

Navkar Q2 FY26 Revenue & EBITDA Growth

News that matters the most ⚡